Preclinical Development of a Lentiviral Vector for Gene Therapy of X-Linked Severe Combined Immunodeficiency.

Mol Ther Methods Clin Dev · 2018 · PMC5918176 · PMID 29707600

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

borderline significantp = 0.07so close (0.05 < p ≤ 0.1)

In these mice, VCNs were on average higher in PB than in the BM (2.04 ± 0.35 versus 1.05 ± 0.40), although the difference was borderline significant (p = 0.07), suggesting a selective advantage in the PB of cells expressing higher levels of IL2RG ( Figure 1 ).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.